BT1.F Bone Therapeutics SA

Healthcare Biotechnology Frankfurt Exchange
0.0020 EUR
Close of Oct 16, 2026
0.0018 0.0030
Market cap
EUR 1.31M
P/E
-
P/B
7.38x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2023.

Is BT1.F undervalued?

Graham number

The Graham number of Bone Therapeutics SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bone Therapeutics SA fundamental analysis

No fundamental analysis for Bone Therapeutics SA yet.

Bone Therapeutics SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bone Therapeutics SA

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Sainte…

Full company profile